Back to top
more

Charles River Laboratories International (CRL)

(Real Time Quote from BATS)

$228.92 USD

228.92
59,877

+1.37 (0.60%)

Updated Apr 19, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.

ICLR or CRL: Which Is the Better Value Stock Right Now?

ICLR vs. CRL: Which Stock Is the Better Value Option?

Charles River (CRL) Forges Collaboration With Ship of Theseus

Charles River (CRL) is set to perform plasmid production for Ship of Theseus.

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.

Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Charles River (CRL) Extends Gene Therapy Offering With New Pact

Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.

Charles River (CRL) Forges Collaboration With Wheeler Bio

Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Charles River (CRL) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Charles River (CRL) Q4 Earnings Surpass, Margins Contract

Charles River (CRL) delivers better-than-expected revenues and earnings in the fourth quarter of 2023.

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.

Unveiling Charles River (CRL) Q4 Outlook: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Charles River (CRL) to Report Q4 Earnings: What's in Store?

The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.

Charles River (CRL) Launches Animal-Free Endotoxin Test

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

Charles River's (CRL) New Launch to Boost Gene Therapy Programs

Charles River's (CRL) latest offering is likely to complete a comprehensive range of off-the-shelf plasmid products and simplify gene therapy supply chains with immediate availability.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.

Charles River's (CRL) Memphis Site Achieves Crucial Approval

Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.

Charles River (CRL) Up 19.7% Since Last Earnings Report: Can It Continue?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.

Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe

At present, Charles River (CRL) is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal

Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.

Charles River (CRL) Widens CliniPrime GMP Suite With New Launch

Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.